| Title |
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, November 2016
|
| DOI | 10.2147/dddt.s103534 |
| Pubmed ID | |
| Authors |
Elizabeth Ashley Hardin, Kelly M Chin |
| Abstract |
Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 30% |
| India | 1 | 10% |
| Mexico | 1 | 10% |
| Unknown | 5 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Scientists | 2 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 21% |
| Student > Master | 6 | 18% |
| Researcher | 4 | 12% |
| Other | 3 | 9% |
| Student > Doctoral Student | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 9 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 29% |
| Biochemistry, Genetics and Molecular Biology | 5 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Agricultural and Biological Sciences | 3 | 9% |
| Nursing and Health Professions | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 10 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2017.
All research outputs
#6,333,477
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#411
of 2,268 outputs
Outputs of similar age
#88,449
of 317,812 outputs
Outputs of similar age from Drug Design, Development and Therapy
#10
of 48 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,812 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.